Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"PARPi"”.
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… Here, it has been shown that PARP inhibitors (PARPis) upregulate PD-L1 expression in multiple cancer cell lines, human xenograft tumors, and syngeneic mouse tumors. Mechanistically, PARPi inactivates GSK3β, which in turn enhances PARPi-mediated PD-L1 upregulation. PARPi attenuates anticancer …
-
Development of Rational Combination Therapy With Parp Inhibitors and Kinase Inhibitors In Tnbc
<p>Poly (ADP-ribose) polymerase inhibitors (PARPi) emerge as potential targeting drugs for BRCA-deficient cancers including triple negative breast cancer (TNBC). However, it has been reported that a subgroup of patients even with BRCA mutation fails to respond to PARPi in multiple clinical trials. …
-
Developing 1,2,3,4-tetrahydro-5H-aryl[1,4]diazepin-5-ones and Related Scaffolds as Poly-(ADP-ribosyl) Polymerase (PARP) Inhibitors and Exploring Their Targeted Polypharmacology with Kinases
… comprised of 17 known isoforms. PARP inhibitors (PARPi) have shown success in clinical trials for the treatment of homologous recombination-deficient cancers. Though proven effective initially, tumors treated with PARPi eventually develop resistance. Combinatorial therapeutics targeting PARP and …
-
PARP inhibition in combination with radiation therapy for the treatment of feline oral squamous cell carcinoma
… stranded DNA break repair. PARP inhibitors (PARPi) are predicted to amplify RT-induced lethal DNA damage, and combinatorial strategies with PARPi and RT are being investigated for treating human solid tumors. We hypothesized that Olaparib, an orally bioavailable PARPi, combined with RT will …
-
EVALUATION OF THE RISK OF SECONDARY LEUKEMIAS IN CANCER SURVIVORS
… 73 lymphomas patients and 58 PARP-inhibitor (PARPi)-eligible ovarian cancer (EOC) patients after platinum-based chemotherapy. We used high-sensitivity error-corrected sequencing (limit of sensitivity VAF>0.1%) for CH analysis, in order to detect mutations well below the cutoff of the clinical …
-
A New Pathway Responsible For 53BP1 Loss in Breast Cancer and Laminopathies
… to current therapies, such as PARP inhibitors: PARPi). Work in our laboratory had previously identified a novel mechanism for regulation of 53BP1 protein levels - degradation by the cysteine protease cathepsin L: CTSL). The main questions addressed in this dissertation are whether CTSL-mediated …
-
CRISPR/Cas9 screenings and in silico investigations nominate low-frequency alterations in DNA repair genes as biomarkers for castration-resistant prostate cancers.
PARP inhibitors (PARPi) have received regulatory approval for the treatment of multiple tumor types, including prostate cancer (PCa), and are associated with therapeutic response in metastatic castration-resistant prostate cancer (mCRPC) patients characterized by defects in homologous recombination …
-
53BP1/Shieldin Counteract DSB Resection Through Fill-In Synthesis
… it determines the efficacy of PARP1 inhibitors (PARPi) in BRCA1-deficient cancers. Additionally, 53BP1 promotes end-to-end fusions of telomeres lacking end protection from the shelterin component TRF2, and facilitates end-joining at programmed breaks generated during class switch recombination in …
-
Glioma genetic profiling: The role of DNA repair and telomerase
… 1), TNKS ( tankyrase), DCKI (dyskerin) and PARPI (poly (ADP-ribose) polymerase1 ) in human glioma compared to normal brain tissues and cell lines. Evidence suggests that hTERT was the only gene that was transcribed in all the glioma cell lines and tissues, while absent in the normal. Thus …